Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Jennifer Robinson MD, MPH

Jennifer G. Robinson MD, MPH

Professor, Departments of Epidemiology & Medicine, Director, Prevention Intervention Center, University of Iowa, Iowa City, Iowa

Jennifer G. Robinson, MD, MPH is a Professor in the Departments of Epidemiology and Medicine (Division of Cardiology), and Director of the Prevention Intervention Center at the University of Iowa, Iowa City, Iowa.

As an active researcher, Dr. Robinson has performed numerous clinical trials sponsored by the National Institutes of Health and the pharmaceutical industry. She has conducted extensive research on a wide range anti-atherosclerotic and metabolic agents, including lipid-modifying, anti-inflammatory, antihypertensive, weight loss, and diabetic treatments as well as postmenopausal hormone therapy. She is the principal investigator for the Women’s Health Initiative (WHI) at the University of Iowa as well as numerous WHI ancillary studies, including the WHI-Mental Status MRI, WHI Study of Cognitive Aging, and the WHI-Coronary Artery Calcium studies. Dr. Robinson has published over 150 peer-reviewed articles in the area of lipids-modifying drugs, cardiovascular risk stratification, and cardiovascular prevention. She has lectured widely on preventive cardiology and the diagnosis and treatment of disorders of lipid metabolism.

She was Vice-Chair for the 2013 American Heart Association/American College of Cardiology Cholesterol Guidelines (formerly known as the National Cholesterol Education Program Adult Treatment Panel IV) and a member of the 2013 American Heart Association/American College of Cardiology Risk Reduction Guidelines (formerly known as the National Heart, Lung, and Blood Institute Risk Reduction Working Group). She is currently the Chair for the National Forum Cholesterol Initiative.

While at the University of Minnesota in Minneapolis, Dr. Robinson received her medical degree and completed an Internal Medicine residency with the College of Medicine, and received a Master’s of Public Health from the College of Public Health. She is a diplomate of the American Boards of Internal Medicine and Clinical Lipidology, and a Fellow of the American Heart Association.


Research grants to Institution: Amarin, Amgen, Astra-Zeneca, Eli Lilly, Esai, Glaxo-Smith Kline, Merck, Pfizer, Regeneron/Sanofi, Takeda.

Consultant: Amgen, Eli Lilly, Merck, Pfizer, Regeneron/Sanofi